Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003894 · ClinicalTrials.gov registry record · Phase 2
Thalidomide in Treating Patients With Chronic Graft-Versus-Host Disease Following Bone Marrow Transplant
A Phase 2 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT00003894 is a Phase 2 study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 36 participants.
The verdict
NCT00003894, a Phase 2 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
RATIONALE: Thalidomide may interfere with the body's ability to recognize transplanted bone marrow cells as foreign and may help treat patients with graft-versus-host disease. PURPOSE: Randomized phase II trial to study the effectiveness of thalidomide in treating patients who have chronic graft-versus-host disease following bone marrow transplantation.
Interventions
- DRUG thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 1999-03 |
| Est. Completion | 2002-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003894
The ClinicalTrials.gov registry entry for NCT00003894 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which thalidomide is the first listed.
NCT00003894 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003894 about?
NCT00003894 is a clinical study titled "Thalidomide in Treating Patients With Chronic Graft-Versus-Host Disease Following Bone Marrow Transplant". RATIONALE: Thalidomide may interfere with the body's ability to recognize transplanted bone marrow cells as foreign and may help treat patients with graft-versus-host disease. PURPOSE: Randomized phase II trial to study the effectiveness of thalidomide in treating patients who have chronic graft-ve...
What is the current status of trial NCT00003894?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 1999-03. Estimated completion is 2002-06.
What interventions are being tested in trial NCT00003894?
The interventions under investigation include: thalidomide (DRUG).
Who is sponsoring clinical trial NCT00003894?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.